InsidersTradesSigma
NFL Biosciences: directors' dealings · France · AMF
RS00007420FR0014003XT0FR·AMFMcap 11M€Healthcare & Pharma
Explore the full insider trade history of NFL Biosciences, a listed equity based in France. Shares trade on FR FR, under the authority of AMF. Operating in the Healthcare & Pharma sector, NFL Biosciences has published 9 reports. Market capitalisation: €11.2m. The latest transaction was disclosed on 8 September 2025 — Cession. Among the most active insiders: Bruno Lafont. The full history is openly available.
9
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
€353,635
5 ops.
Sell Volume
Financial data
FY ended December 2025 · cache
0.89 €
Analyst consensus
Income statement
Gross profit−2.5 M€
Net income−3.3 M€0.0% margin
Valuation
P/Book8.9x
Beta1.15
Balance sheet & cash
Market cap11.2 M€
Total debt583 k€
Profitability & ownership
% insiders14.2%
% institutions0.0%
Last declaration on 8 September 2025
Declarations9 total
Executives▼Sale20AMF
€27,40518,000 shares@ €1.52250.14% mcap5.9% of flow
ActionEuronext Growth Paris
2025DD1056681·
Executives▼Sale22AMF
€49,48941,650 shares@ €1.18820.26% mcap10.7% of flow
ActionEuronext Growth Paris
2025DD1049758·
Executives◇Options24AMF
€75,000250,000 shares@ €0.300.39% mcap16.2% of flow
ActionEuronext Growth Paris
2025DD1032010·
Executives▼Sale40AMF
€16,9556,568 shares@ €2.58140.088% mcap100.0% of flow
ActionEuronext Growth Paris
2023DD920561·
Executives◇Options24AMF
€50,000500,000 shares@ €0.100.26% mcap10.8% of flow
ActionEuronext Growth Paris
2023DD918253·
Executives▼Sale40AMF
€151,27257,000 shares@ €2.65390.78% mcap32.8% of flow
ActionEuronext Growth Paris
2023DD918168·
Executives▼Sale39AMF
€108,51543,000 shares@ €2.52360.56% mcap23.5% of flow
ActionEuronext Growth Paris
2023DD918207·
Executives◆Grant14AMF
071,778 shares0
ActionEuronext Growth Paris
2023DD896929·
9 of 9 declarations
About NFL Biosciences
NFL BIOSCIENCES is a French biopharmaceutical company listed on Euronext Growth Paris under ISIN FR0014003XT0 and ticker ALNFL. Headquartered in Castelnau-le-Lez, near Montpellier, the company develops innovative botanical medicines for the treatment of addictions, with a long-standing focus on smoking cessation. Its model is that of a specialty biotech centered on plant-derived drug candidates, designed to be licensed to pharmaceutical partners rather than widely marketed directly by the company. This partnership-led strategy allows NFL BIOSCIENCES to concentrate on research, clinical validation and intellectual property value creation. The company was co-founded in 2009 by Bruno Lafont, who now serves as Chairman of the Board and CEO, with the ambition of turning botanical extracts into standardized, reproducible therapies that can meet strict regulatory requirements. Its pipeline is built around several programs. NFL-101 is the most advanced candidate; it is a standardized tobacco-leaf extract developed to help smokers quit. NFL-102 is another smoking-cessation candidate aimed at a broader population, while NFL-301 is focused on excessive alcohol consumption and is based on kudzu extract. The company emphasizes a scientific approach rooted in the biology of addiction, aiming to go beyond symptom relief and address the underlying neurobiological mechanisms that drive dependence and relapse. NFL BIOSCIENCES also stands out for its structured intellectual-property portfolio, which includes multiple patent families, and for its lean operating model with outsourced research and controlled fixed costs. Manufacturing is carried out in France in compliance with Good Manufacturing Practices, reinforcing the industrial credibility of the platform. In 2025 and early 2026, the company continued to advance its clinical and regulatory programs while securing additional funding from long-standing supporters such as Bpifrance. Following an April 2026 bond financing, its cash runway was extended to the third quarter of 2027, an important visibility factor for a pre-commercial biotech. Overall, NFL BIOSCIENCES is positioned as a niche French biotechnology company with exposure to the addiction-treatment market and a value-creation strategy centered on licensing.
